Only in Titles

           Search results for: SYNTHETIC HUMAN BMP-4-PURIFIED PROTEIN   

paperclip

#29054092   2017/10/20 Save this To Up

Protein-mimicking nanoparticles for the reproduction of transient protein-receptor interactions.

One of the major concerns in target identification has been the need for new methods to detect target molecules in the native cellular environment. In conventional target identification, affinity-based pull down has been conducted using cell lysates. However, interactions in cell lysate do not reflect real endogenous interactions in living cells, and can produce false-positive or false-negative results. This study aimed to develop a new method of target protein identification in living cells. Targeting probes were conjugated onto magnetic nanoparticles (MNPs). After nanoparticle cellular uptake, identification and recruitment of target proteins were conducted in living cells, and the target protein was finally recovered under the magnetic field. As a proof-of-concept study, we developed a functionalized MNP (PTS1-MNP) to mimic a peroxisomal protein containing a synthetic peroxisomal targeting signal 1 (PTS1). The PTS1-MNPs were imported into human hepatoma HepG2 cells to recruit PTS1-receptor protein Pex5p. Successful peroxisomal translocation of PTS-MNPs was achieved via transient interaction with Pex5p. Pull-down of Pex5p in lysed or living HepG2 cells confirmed the selective recruiting functionality of synthetic PTS1. The specific detection of Pex5p before complete PTS1-MNPs translocation in living HepG2 cells further demonstrated the transient interaction between Pex5p and PTS1-MNPs. This is the first report showing the peroxisomal translocation of nanostructured materials in living cells. This approach can be applied as a new concept to study transient interactions and target identification or recruiting in living cells.

2261 related Products with: Protein-mimicking nanoparticles for the reproduction of transient protein-receptor interactions.

Bone Morphogenetic Protei G protein-coupled recepto G protein-coupled recepto G protein-coupled recepto G protein-coupled recepto G protein-coupled recepto Protein A (Liquid form) Protein A (Liquid form) Protein A (Liquid form) Protein A (Liquid form) NATIVE HUMAN PROLACTIN, P TNF Receptor-Associated P

Related Pathways

paperclip

#29049722   2017/10/19 Save this To Up

A PPAR-Gamma Agonist Rosiglitazone Suppresses Fibrotic Response in Human Pterygium Fibroblasts by Modulating the p38 MAPK Pathway.

Fibroblast activation may play an important role in pterygium progression. Synthetic peroxisome proliferator-activated receptor γ (PPAR-γ) ligands have been shown to be effective antifibrotic agents against transforming growth factor β1 (TGF-β1) induced fibrosis in several tissues. We aimed to investigate the antifibrotic effects of the PPAR-γ ligand rosiglitazone in pterygium fibroblasts and the underlying mechanisms.

1534 related Products with: A PPAR-Gamma Agonist Rosiglitazone Suppresses Fibrotic Response in Human Pterygium Fibroblasts by Modulating the p38 MAPK Pathway.

P38 MAPK(Phospho-Thr180 T Anti beta3 AR Human, Poly GPCR Signaling to MAPK ER MAPK Phospho-Specific Arr Goat Anti-Human ERK2 MAPK Goat Anti-Human RXR gamma Goat Anti-Human Tissue Fa Mouse anti human INF gamm Mouse anti human INF gamm Anti AGO2 Human, Monoclon Anti AGO2 Human, Monoclon Human Macrophage Inflamma

Related Pathways

paperclip

#29047390   2017/10/19 Save this To Up

Roles of BCCIP deficiency in mammary tumorigenesis.

Dysregulated DNA repair and cell proliferation controls are essential driving forces in mammary tumorigenesis. BCCIP was originally identified as a BRCA2 and CDKN1A interacting protein that has been implicated in maintenance of genomic stability, cell cycle regulation, and microtubule dynamics. The aims of this study were to determine whether BCCIP deficiency contributes to mammary tumorigenesis, especially for a subset of breast cancers with 53BP1 abnormality, and to reveal the mechanistic implications of BCCIP in breast cancer interventions.

1583 related Products with: Roles of BCCIP deficiency in mammary tumorigenesis.

Human Internal Mammary Ar GFP Expressing Human Inte Interleukin-34 IL34 (N-t Interleukin-34 IL34 anti Sterile filtered goat se Sterile filtered goat se Sterile filtered mouse s Sterile filtered rat ser ING1B antisense ING1B sense Interferon γ p19 INK4D

Related Pathways

paperclip

#29040754   2017/10/17 Save this To Up

Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.

As a stress-inducible natural killer (NK) cell ligand, B7H6 plays a role in innate tumor immunosurveillance and is a fairly tumor selective marker expressed on a variety of solid and hematologic cancer cells. Here, we describe the isolation and characterization of a new family of single chain fragment variable (scFv) molecules targeting the human B7H6 ligand. Through directed evolution of a yeast surface displayed non-immune human-derived scFv library, eight candidates comprising a single family of clones differing by up to four amino acid mutations and exhibiting nM avidities for soluble B7H6-Ig were isolated. A representative clone re-formatted as an scFv-CH1-Fc molecule demonstrated specific binding to both B7H6-Ig and native membrane-bound B7H6 on tumor cell lines with a binding avidity comparable to the previously characterized B7H6-targeting antibody, TZ47. Furthermore, these clones recognized an epitope distinct from that of TZ47 and the natural NK cell ligand NKp30, and demonstrated specific activity against B7H6-expressing tumor cells when expressed as a chimeric antigen receptor (CAR) in T cells.

2202 related Products with: Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.

anti HBsAg surface antige anti CD54 IgG2b k monoclo anti CD66e IgG1 monoclona anti RhoD human antigen I anti A1, A2 human blood a anti A1, A2, A3 human blo anti B human blood antige anti AB human blood antig anti Rh(o)D human antigen anti Rh(o)D and Rh(o)Dii anti RhoC human Rhesus sy Blood Group Antibodies a

Related Pathways

paperclip

#29039762   2017/10/17 Save this To Up

Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.

A large diversity of 2-aminoimidazolone alkaloids is produced by various marine invertebrates, especially by the marine Calcareous sponges Leucetta and Clathrina. The phylogeny of these sponges and the wide scope of 2-aminoimidazolone alkaloids they produce are reviewed in this article. The origin (invertebrate cells, associated microorganisms, or filtered plankton), physiological functions, and natural molecular targets of these alkaloids are largely unknown. Following the identification of leucettamine B as an inhibitor of selected protein kinases, we synthesized a family of analogues, collectively named leucettines, as potent inhibitors of DYRKs (dual-specificity, tyrosine phosphorylation regulated kinases) and CLKs (cdc2-like kinases) and potential pharmacological leads for the treatment of several diseases, including Alzheimer's disease and Down syndrome. We assembled a small library of marine sponge- and ascidian-derived 2-aminoimidazolone alkaloids, along with several synthetic analogues, and tested them on a panel of mammalian and protozoan kinases. Polyandrocarpamines A and B were found to be potent and selective inhibitors of DYRKs and CLKs. They inhibited cyclin D1 phosphorylation on a DYRK1A phosphosite in cultured cells. 2-Aminoimidazolones thus represent a promising chemical scaffold for the design of potential therapeutic drug candidates acting as specific inhibitors of disease-relevant kinases, and possibly other disease-relevant targets.

2169 related Products with: Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.

Primary antibody DRAK2 A Rat monoclonal anti mouse Factor VIII Related Anti Factor VIII Related Anti Factor VIII Related Anti HIV type O envelope antig CELLKINES PLATELET DERIVE PLATELET DERIVED GROWTH F CELLKINES PLATELET DERIVE PLATELET DERIVED GROWTH F Human Brain Derived Neuro Human Glial Derived Neuro

Related Pathways

  •  
  • No related Items
paperclip

#29039460   2017/10/17 Save this To Up

Characterization of tree shrew (Tupaia belangeri) interleukin-6 and its expression pattern in response to exogenous challenge.

Tree shrews, one of the closest relatives of primates, have attracted increasing attention as a model of human diseases, particularly for viral infections. As the first line of defense against microbial pathogens, the innate immune system is crucial in tree shrews. Interleukin-6 (IL-6) is important in the pathophysiology of infection, inflammation and cancer, where it promotes disease development or sustains immune reactions. The present study aimed to obtain further insight into the tree shrew IL-6 (tsIL-6) system, and the function of tsIL-6 in the antiviral and antibacterial response. In the present study, the mRNA and genomic sequence of the tsIL-6 gene were characterized, and the tissue distribution and expression profile of this gene were analyzed in response to lipopolysaccharide (LPS) and polyinosinic:polycytidylic acid (poly I:C) treatment. The full-length tsIL-6 mRNA consisted of 1,152 bp with an open reading frame of 627 bp encoding 208 amino acids, a 5'-untranslated region (UTR) of 62 bp, and a 3'-UTR of 436 bp. The genome sequence of the tsIL-6 gene was 5,265 bp in length, comprising of five exons and four introns. The predicted tsIL-6 protein contained a 25-amino-acid-long signal peptide and a conserved IL-6 domain. Phylogenetic analysis based on the coding sequences revealed that tsIL-6 was closely related to IL-6 in humans. Residues crucial for receptor binding were completely conserved in the tree shrew protein. Reverse transcription-polymerase chain reaction analysis revealed that tsIL-6 mRNA was expressed in all examined tissues of healthy tree shrews, with high levels in the muscle and spleen. Following poly I:C challenge, the expression levels of tsIL-6 were upregulated in four tissues associated with immune system, the liver, spleen, kidney and intestine. Taken together, the molecular and bioinformatics analyses based on the IL-6 sequence revealed that the tree shrew has a close phylogenetic association with humans. These results provide insight for future investigations on the structure and function of tsIL-6.

1233 related Products with: Characterization of tree shrew (Tupaia belangeri) interleukin-6 and its expression pattern in response to exogenous challenge.

5-Bromo-6-chloro-3-indoly (BCIP Toluidine)5 Bromo 4 Oral squamous cell cancer ELISA Mouse , Interleukin Interleukin-34 IL34 (N-t Interleukin-34 IL34 anti CELLKINES Natural Human I CELLKINES INTERLEUKIN 2 ( INTERLEUKIN 2 (rIL 2) CELLKINES INTERLEUKIN 2 ( INTERLEUKIN 2 (rIL 2) DNA (cytosine 5) methyltr

Related Pathways

  •  
  • No related Items
paperclip

#29033499   2017/10/16 Save this To Up

Fabrication and Characterization of Electrospun Thermoplastic Polyurethane/Fibroin Small-Diameter Vascular Grafts for Vascular Tissue Engineering.

The demand for small-diameter blood vessel substitutes has been increasing due to a shortage of autograft vessels and problems with thrombosis and intimal hyperplasia with synthetic grafts. In this study, hybrid small-diameter vascular grafts made of thermoplastic polyurethane (TPU) and silk fibroin, which possessed a hybrid fibrous structure of an aligned inner layer and a random outer layer, were fabricated by the electrospinning technique using a customized striated collector that generated both aligned and random fibers simultaneously. A methanol post-treatment process induced the transition of fibroin protein conformation from the water-soluble, amorphous, and less ordered structures to the water-insoluble β-sheet structures that possessed robust mechanical properties and relatively slow proteolytic degradation. The methanol post-treatment also created crimped fibers that mimicked the wavy structure of collagen fibers in natural blood vessels. Ultrafine nanofibers and nanowebs were found on the electrospun TPU/fibroin samples, which effectively increased the surface area for cell adhesion and migration. Cyclic circumferential tensile test results showed compatible mechanical properties for grafts made of a soft TPU/fibroin blend compared to human coronary arteries. In addition, cell culture tests with endothelial cells after 6 and 60 days of culture exhibited high cell viability and good biocompatibility of TPU/fibroin grafts, suggesting the potential of applying electrospun TPU/fibroin grafts in vascular tissue engineering.

1991 related Products with: Fabrication and Characterization of Electrospun Thermoplastic Polyurethane/Fibroin Small-Diameter Vascular Grafts for Vascular Tissue Engineering.

Multiple lung carcinoma ( Human Endocrine Gland Vas Human Vascular Endothelia Human Vascular Endothelia Mouse Vascular Endothelia Mouse Vascular Endothelia Alkaline Phospatase (ALP) Rat Vascular Endothelial Non small cell lung carci Non small cell lung carci Non small cell lung carci Breast invasive ductal ca

Related Pathways

paperclip

#29032169   2017/10/16 Save this To Up

Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.

Hepatocytes represent an important target for gene therapy and editing of single-gene disorders. In α-1 antitrypsin (AAT) deficiency, one missense mutation results in impaired secretion of AAT. In most patients, lung damage occurs due to a lack of AAT-mediated protection of lung elastin from neutrophil elastase. In some patients, accumulation of misfolded PiZ mutant AAT protein triggers hepatocyte injury, leading to inflammation and cirrhosis. We hypothesized that correcting the Z mutant defect in hepatocytes would confer a selective advantage for repopulation of hepatocytes within an intact liver. A human PiZ allele was crossed onto an immune-deficient (NSG) strain to create a recipient strain (NSG-PiZ) for human hepatocyte xenotransplantation. Results indicate that NSG-PiZ recipients support heightened engraftment of normal human primary hepatocytes as compared with NSG recipients. This model can therefore be used to test hepatocyte cell therapies for AATD, but more broadly it serves as a simple, highly reproducible liver xenograft model. Finally, a promoterless adeno-associated virus (AAV) vector, expressing a wild-type AAT and a synthetic miRNA to silence the endogenous allele, was integrated into the albumin locus. This gene-editing approach leads to a selective advantage of edited hepatocytes, by silencing the mutant protein and augmenting normal AAT production, and improvement of the liver pathology.

2146 related Products with: Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.

Bone Morphogenetic Protei Growth Differentiation Fa Rabbit Anti-Human Androge succinate-CoA ligase, GDP formin-like 1 antibody So succinate-CoA ligase, ADP Human PAI-1 (stable mutan Recombinant Human Androge MOUSE ANTI HUMAN CD19 RPE Uroguanylin (circulating ELISA Kit for A Disinteg Formalin Solution (20%)

Related Pathways

paperclip

#29032033   2017/10/16 Save this To Up

Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier.

Neuroinflammation is the earliest stage of several neurological and neurodegenerative diseases. In the case of neurodegenerative disorders, it takes place about 15-20 years before the appearance of specific neurodegenerative clinical symptoms. Constitutive microglial COX-1 is one of the pro-inflammatory players of the neuroinflammation. Novel compounds 3, 14 and 15 (Galmof0, Galmof5 and Galmof11, respectively) were projected, and their synthetic methodologies developed, by linking by an ester bond, directly or through a C5 or C11 unit linker the highly selective COX-1 inhibitor mofezolac (COXs selectivity index > 6000) to galactose in order to obtain substances capable to cross blood-brain barrier (BBB) and control the CNS inflammatory response. 3, 14 and 15 (Galmofs) were prepared in good to fair yields. Galmof0 (3) was found to be a selective COX-1 inhibitor (COX-1 IC50 = 0.27 μM and COX-2 IC50 = 3.1 μM, selectivity index = 11.5), chemically and metabolically stable, and capable to cross Caco-2 cell monolayer, resembling BBB, probing that its transport is GLUT-1-mediated. Furthermore, Galmof0 (3) powerfully inhibits PGE2 release higher than mofezolac (1) in LPS-stimulated mouse BV2 microglial cell line, a worldwide recognized neuroinflammation model. In addition, Fingerprints for Ligands and Proteins (FLAP) was used to explain the different binding interactions of Galmofs with the COX-1 active site.

1134 related Products with: Effect of mofezolac-galactose distance in conjugates targeting cyclooxygenase (COX)-1 and CNS GLUT-1 carrier.

Goat Anti-Human Sterol ca BCIP INT Solution Sterile filtered goat se Sterile filtered rat ser Anti AGO2 Human, Monoclon Anti AGO2 Mouse, Monoclon anti HCMV IE pp65 IgG1 (m anti HCMV gB IgG1 (monocl Insulin 1 (Rat), syntheti CELLKINES INTERLEUKIN 2 ( INTERLEUKIN 2 (rIL 2) CELLKINES INTERLEUKIN 2 (

Related Pathways

paperclip

#29031806   2017/10/16 Save this To Up

Tumor suppressive protein phosphatases in human cancer: emerging targets for therapeutic intervention and tumor stratification.

Aberrant protein phosphorylation is one of the hallmarks of cancer cells, and in many cases a prerequisite to sustain tumor development and progression. Like protein kinases, protein phosphatases are key regulators of cell signaling. However, their contribution to aberrant signaling in cancer cells is overall less well appreciated, and therefore, their clinical potential remains largely unexploited. In this review, we provide an overview of tumor suppressive protein phosphatases in human cancer. Along their mechanisms of inactivation in defined cancer contexts, we give an overview of their functional roles in diverse signaling pathways that contribute to their tumor suppressive abilities. Finally, we discuss their emerging roles as predictive or prognostic markers, their potential as synthetic lethality targets, and the current feasibility of their reactivation with pharmacologic compounds as promising new cancer therapies. We conclude that their inclusion in clinical practice has obvious potential to significantly improve therapeutic outcome in various ways, and should now definitely be pushed forward.

2077 related Products with: Tumor suppressive protein phosphatases in human cancer: emerging targets for therapeutic intervention and tumor stratification.

Recombinant Human Tumor P Multiple organ tumor tiss Multiple organ tumor tiss Multiple organ tumor tiss Liver cancer tissue array Multiple organ cancer tis Multiple organ tumor tiss Total Protein Human Tumor Human, Complement C1q tum Bone Morphogenetic Protei Human Tumor Necrosis Fact Human Macrophage Inflamma

Related Pathways